The GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with Pixantrone for the treatment of patients with relapsed aggressive B-cell Lymphoma
Laufzeit: 01.01.2015 - 31.12.2022
Kurzfassung
Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with Pixantronefor the treatment of patients with relapsed aggressive B-cell Lymphoma - The GOAL trial
